NEW YORK (AP) - Shares of Alkermes Inc. declined Wednesday as investors weighed potential bad news for one drug Alkermes helped develop with good news for another.
NEW YORK (AP) - Shares of Bristol-Myers Squibb Co. dipped Wednesday after the drug developer said its developing blood thinner apixaban failed in a late-stage study.
Cordis Corporation today announced that it has received CE mark approval to market the CYPHER SELECT® Plus Sirolimus-eluting Coronary Stent for the treatment of acute myocardial infarction (AMI),
Will video games be coming to an enterprise near you? Forrester Research seems to think so as companies cook up new ways to train employees–especially those so-called millennial.
I can hear the laughter now. Video games? We’re about serious business, you’ll say. What’s the ROI you’ll ask? Video games aren’t serious–they are a productivity killer. I can’t even get my CFO to upgrade Windows 98 desktops!
Below we highlight the 30 largest companies in the World by market cap ($). As shown, Exxon Mobil (XOM) is the top dog by about $70 billion. Exxon is trailed by another energy company, Petrochina (PTR), then General Electric (GE) and Microsoft (MSFT).
Eleven of the top 30 are based in the United States. The Energy sector has the largest representation at 8, followed by Technology at 5. Only 3 companies in the top 30 are up in 2008 -- Wal-Mart (WMT), IBM (IBM) and Johnson & Johnson...
Barry Ritholtz over at the Big Picture recently highlightedBloomberg'sChart of the Day showing that analyst profit forecasts are currently worse than ever.
With that in mind, we pulled up a post we did back in November highlighting the average analyst price targets for the 30 Dow stocks. After analyzing those price targets and where the stocks are now, it's clear that bear markets are definitely not an analyst's best friend.
Our Director of Zacks Equity Research Dirk van Dijk, CFA slices and dices all sorts of data on publicly traded industries. Recently, we got his take on something called a “revisions ratio,” and managed to get a few Buy recommendations in the process.
You track something called a “revisions ratio.” Could you tell us a little about it?
If the 11% gain by Nasdaq in mid-July isn't a summer rally, I don't know what is. They talk about it nearly every year, and it never happens, yet this year it arrived when it was expected least, as the market continues to labor under the shadow of the crisis in the banks sector.
The rally was exceptionally pronounced on Nasdaq because of the influx of funds to tech stocks, but the climb by the Russell 2000 was higher still - 14% from mid-July as investors piled into small...
Now that more than half the year is behind us, I thought it would be interesting to look at my top 5 performers through July 31, 2008. As dismal as the stock market has been this year, there are still some bright spots. My top five performers have all achieved double-digit positive total returns since I owned them and positive returns in 2008. Here they are with comments: #5 - McDonald's (MCD) + 4.4% Total 2008 Return Last November, I bought this burger maker for $57 in spite of only paying one dividend per year....
Even my clients have grown despondent in their concerns and fears that the market's triumphal march higher has ended, and with its ending chimes the death knell of the investment opportunities I favor (and guide their portfolios toward). Certainly, the ~9 month decline calculates as among the more unbearable, but "the market you are in always feels like the worst."
I attempt to keep my readers (and clients' portfolios) on the right side of the market; for example, warning and assuming a defensive posture last...
Johnson & Johnson ( NYSE : JNJ ) is having a rough couple of weeks.Last week , the Food and Drug Administration turned down its request to expand the label of its antibiotic Doribax , and on ...
The US Food and Drug Administration ( FDA ) has requested more data on a schizophrenia treatment developed by Johnson & Johnson ( J&J ).J&J has been sent a " complete response " letter from the ...
The FDA issued a " complete response " letter seeking more data on Johnson & Johnson's paliperidone palmitate before deciding whether the schizophrenia treatment can enter the US market.J&J said ...
Grab this all - in - one application and get recaps of the show sent right to your desktop or blog.Check out Cramer on set , back to school , behind the scenes and more.Buy Cramer books , bobbleheads ...
The US Food and Drug Administration has asked Johnson & Johnson ( JNJ ) for additional data before it will approve paliperidone palmitate , a schizophrenia drug.The agency outlined questions ...
Rhei Pharmaceuticals Inc . has found its new CEO in Geert Cauwenbergh , a serial life sciences entrepreneur and ex - Johnson & Johnson ( NYSE : JNJ ) R&D executive.Cauwenbergh replaces the late ...
Company Receives Approval from Chinese Health Authorities to Launch Final Clinical Trial for Asacard ( R ) NEW HAVEN , Conn . , Aug . 25 / PRNewswire / - - RHEI Pharmaceuticals , Inc . today ...
US health care giant Johnson & Johnson says that the Food and Drug Administration requires additional information before it will approve the company's New Drug Application for Doribax ( doripenem ...
Johnson & Johnson failed to win FDA approval to market Doribax for hospital - acquired pneumonia despite an expert panel's positive recommendation.The agency sought more data on the antibiotic ...
The FDA hasn ' t exactly said " no " to Johnson & Johnson's Doribax , but it has definitely said " not yet . " J&J had asked the agency to expand the use of the IV antibiotic to hospital - acquired ...
NEW YORK (MarketWatch) -- Johnson & Johnson's Pharmaceutical
Research & Development unit said Thursday that the U.S. Food and Drug Administration has asked for additional information before it will approve the company's new drug application for Doribax -- an injectable form of doripenem -- for the treatment of hospital-acquired pneumonia. The company said it is reviewing the agency's letter and will work to resolve any outstanding questions on the application, originally filed in June 2007.
LONDON (MarketWatch) -- UBS downgraded Johnson & Johnson to neutral from buy, citing valuation. The stock closed Thursday at $71.19 and is up about 12% since late June.
Alzheimer's disease is the leading cause of dementia in older people, caused by the widespread destruction of brain cells called neurons over the span of several years.
SAN FRANCISCO (MarketWatch) -- Healthcare product makers Wyeth and Johnson & Johnson Inc. both said in filings with the Securities and Exchange Commission Monday that they have been served with federal subpoenas over marketing of respective products. Wyeth said that it received additional subpoenas from the United States Attorney's Office in Massachusetts for documents related to the company's marketing and pricing of its acid reflux medication Protonix. J&J said that it received a subpoena from the same office in June related to the marketing of biliary stents by its Cordis unit. Biliary stents are tubes inserted into the...
Stocks 
Larry Dignan (
Hickey and Walters (
